Pulse Biosciences Expands Equity Incentive Plan

An update from Pulse Biosciences ( (PLSE) ) is now available.

On September 30, 2025, Pulse Biosciences held a special meeting where stockholders approved amendments to the 2017 Equity Incentive Plan, increasing the shares issuable by two million and expanding the definition of ‘Consultant.’ They also ratified options for directors and consultants, including CEO Paul A. LaViolette, to purchase up to 600,000 shares. These decisions aim to enhance the company’s strategic flexibility and incentivize key personnel, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.

Spark’s Take on PLSE Stock

According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.

Pulse Biosciences receives a low overall score due to persistent financial challenges such as continuous losses and cash burn. While technical indicators show some positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided a balanced view with notable advancements in technology and strengthened finances, but increased operational costs remain a concern. The CFO appointment is a positive strategic move but does not significantly affect the overall score.

To see Spark’s full report on PLSE stock, click here.

More about Pulse Biosciences

Pulse Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative health solutions. The company primarily offers products and services related to medical technology and is involved in creating novel therapeutic options.

Average Trading Volume: 182,347

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.2B

See more insights into PLSE stock on TipRanks’ Stock Analysis page.